search
Back to results

TB Screening Improves Preventive Therapy Uptake (TB SCRIPT)

Primary Purpose

Tuberculosis, Latent Tuberculosis, Tuberculosis Prevention

Status
Recruiting
Phase
Not Applicable
Locations
Uganda
Study Type
Interventional
Intervention
CRP, point-of-care assay
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Tuberculosis focused on measuring Tuberculosis, Latent tuberculosis, Tuberculosis preventive therapy, HIV, C-reactive protein, Symptom screening, Intensified case finding

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • Confirmed HIV+ test result
  • CD4 T lymphocyte count of ≤ 350 cells/μL
  • Capacity to provide written (or witnessed verbal, if illiterate) informed consent

Exclusion Criteria:

  • Completed treatment for active pulmonary or extra-pulmonary TB within the past 2 years
  • Completed a full course of TPT within the past year
  • Actively taking any internationally-approved medication for TB treatment for any reason, within 2 weeks of study entry
  • Prior history of combined ART for HIV treatment for any duration (does not include single-dose ART for prevention of vertical transmission of HIV)
  • Currently resides 25 km outside their enrollment site, plans to move 25 km outside their enrollment site in the next 2 years, or plans to transfer their HIV care from their current enrollment site

Sites / Locations

  • Kampala Capital City Authority ClinicRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

POC CRP-based TB screening

Symptom-based TB screening

Arm Description

Participants randomized to the intervention arm will undergo POC CRP-based TB screening at study entry. Participants with elevated POC CRP levels (≥8 mg/L) will be regarded as screen-positive and will be referred for confirmatory TB testing. Participants with non-elevated POC CRP levels (<8 mg/L) will be regarded as screen-negative and will be assessed for TPT eligibility.

Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.

Outcomes

Primary Outcome Measures

Microbiologically-confirmed incident TB and all-cause mortality
Time to first diagnosis of microbiologically-confirmed incident TB or death from any cause

Secondary Outcome Measures

TB incidence: number diagnosed
Number diagnosed with microbiologically-confirmed incident TB
TB incidence: incidence
Incidence of microbiologically-confirmed TB (excluding prevalent TB cases)
TB incidence: Time to microbiologically-confirmed incident TB diagnosis
Days from three months post-enrollment to incident TB diagnosis (or censoring)
TB incidence: incidence rate
Incident rate of microbiologically-confirmed TB
TB incidence: drug resistant TB
Number diagnosed with drug-resistant incident TB
TB incidence: drug resistant TB among people receiving TPT
Proportion of participants receiving TPT diagnosed with incident drug resistant TB
Mortality: number of deaths from any cause
Number who died from any cause
Mortality: time to death from any cause
Number of days from enrollment to death from any cause
Mortality: all-cause death rate
Rate of deaths from any cause
Mortality: number who died from TB
Number who died from confirmed or probable TB
TPT uptake: number screen-negatives prescribed TPT
Number of screen-negatives prescribed TPT
TPT uptake: number screen-positives prescribed TPT
Number screen-positives prescribed TPT
TPT uptake: number initiated on TPT
Number screen-negatives prescribed TPT + number screen-positives prescribed TPT
TPT uptake: time to TPT initiation
Days from baseline TB screening to initiation of TPT
TPT uptake: number completing TPT
Number initiated on TPT who completed ≥90% of treatment over prescribed TPT period
Prevalent TB diagnosis: number microbiologically-confirmed prevalent TB cases detected by screening test
Number screen-positives diagnosed with prevalent TB
Prevalent TB diagnosis: number microbiologically-confirmed prevalent TB cases missed by screening test
Number screen-negatives diagnosed with prevalent TB
Prevalent TB diagnosis: number diagnosed with microbiologically-confirmed prevalent TB
Number screen-positives diagnosed with prevalent TB + number screen-negatives diagnosed with prevalent TB
Prevalent TB treatment: Number treated for prevalent TB
Number initiated on TB treatment 3 months or less after study entry
Prevalent TB treatment: number with microbiologically-confirmed prevalent TB completing treatment
Number diagnosed and treated who completed treatment
Prevalent TB treatment: time to treatment of microbiologically-confirmed prevalent TB
Days from prevalent TB diagnosis to initiation of TB treatment

Full Information

First Posted
September 14, 2020
Last Updated
April 21, 2022
Sponsor
University of California, San Francisco
Collaborators
Makerere University, Infectious Diseases Research Collaboration, Uganda, Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT04557176
Brief Title
TB Screening Improves Preventive Therapy Uptake
Acronym
TB SCRIPT
Official Title
TB Screening Improves Preventive Therapy Uptake Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 16, 2020 (Actual)
Primary Completion Date
March 15, 2025 (Anticipated)
Study Completion Date
March 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
Makerere University, Infectious Diseases Research Collaboration, Uganda, Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
HIV-infected people have an increased risk of developing active tuberculosis (TB). To reduce the burden of TB among people living with HIV (PLHIV), the World Health Organization (WHO) recommends systematic TB screening followed by 1) confirmatory TB testing for all those who screen positive and 2) TB preventive therapy (TPT) for all TPT-eligible PLHIV who screen negative. The objective of the TB Screening Improves Preventive Therapy Uptake (TB SCRIPT) trial is to determine whether TB screening based on C-reactive protein (CRP) levels, measured using a rapid and low-cost point-of-care (POC) assay, improves TPT uptake and clinical outcomes of PLHIV, relative to symptom-based TB screening.
Detailed Description
The overall objective of the TB SCRIPT trial is to evaluate the effectiveness and cost-effectiveness of POC CRP-based TB screening, which is the next step required for successful scale-up of both systematic TB screening and TPT. The study's central hypothesis is that compared to symptom-based TB screening, a TB screening strategy based on CRP levels measured at the point-of-care will improve TPT uptake, thereby reducing TB incidence and its associated mortality among PLHIV. To test this hypothesis, the investigators will conduct an individual randomized control trial enrolling PLHIV presenting to clinics in Uganda for routine antiretroviral therapy (ART) initiation. Eligible participants will be randomized to either POC CRP-based TB screening (intervention arm) or symptom-based TB screening (control arm). In both arms, screen-positive participants will undergo confirmatory TB testing; participants found to have prevalent TB will be initiated on standard TB treatment. In both arms, screen-negative participants will be assessed for TPT eligibility; TPT-eligible participants will be initiated on standard TPT. All participants will be followed for 2 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis, Latent Tuberculosis, Tuberculosis Prevention, HIV
Keywords
Tuberculosis, Latent tuberculosis, Tuberculosis preventive therapy, HIV, C-reactive protein, Symptom screening, Intensified case finding

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Masking will be maintained by administering finger prick tests to all participants, irrespective of trial arm. Intervention arm participants will have CRP levels measured from blood obtained by finger prick. Control arm participants will have beta-human chorionic gonadotropin (beta-hCG) levels measured from blood obtained by finger prick. Only participants, study investigators and routine clinical care providers will be masked. Study staff performing TB screening in accordance with the participant's randomization assignment and activities downstream of TB screening (i.e., confirmatory TB testing, TPT eligibility assessment) will not be masked. The database administrator will have access to the randomized assignments.
Allocation
Randomized
Enrollment
1720 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
POC CRP-based TB screening
Arm Type
Experimental
Arm Description
Participants randomized to the intervention arm will undergo POC CRP-based TB screening at study entry. Participants with elevated POC CRP levels (≥8 mg/L) will be regarded as screen-positive and will be referred for confirmatory TB testing. Participants with non-elevated POC CRP levels (<8 mg/L) will be regarded as screen-negative and will be assessed for TPT eligibility.
Arm Title
Symptom-based TB screening
Arm Type
No Intervention
Arm Description
Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.
Intervention Type
Device
Intervention Name(s)
CRP, point-of-care assay
Other Intervention Name(s)
iCHROMA CRP reader, Boditech Med Inc.
Intervention Description
CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
Primary Outcome Measure Information:
Title
Microbiologically-confirmed incident TB and all-cause mortality
Description
Time to first diagnosis of microbiologically-confirmed incident TB or death from any cause
Time Frame
two years
Secondary Outcome Measure Information:
Title
TB incidence: number diagnosed
Description
Number diagnosed with microbiologically-confirmed incident TB
Time Frame
two years
Title
TB incidence: incidence
Description
Incidence of microbiologically-confirmed TB (excluding prevalent TB cases)
Time Frame
two years
Title
TB incidence: Time to microbiologically-confirmed incident TB diagnosis
Description
Days from three months post-enrollment to incident TB diagnosis (or censoring)
Time Frame
two years
Title
TB incidence: incidence rate
Description
Incident rate of microbiologically-confirmed TB
Time Frame
two years
Title
TB incidence: drug resistant TB
Description
Number diagnosed with drug-resistant incident TB
Time Frame
two years
Title
TB incidence: drug resistant TB among people receiving TPT
Description
Proportion of participants receiving TPT diagnosed with incident drug resistant TB
Time Frame
two years
Title
Mortality: number of deaths from any cause
Description
Number who died from any cause
Time Frame
two years
Title
Mortality: time to death from any cause
Description
Number of days from enrollment to death from any cause
Time Frame
two years
Title
Mortality: all-cause death rate
Description
Rate of deaths from any cause
Time Frame
two years
Title
Mortality: number who died from TB
Description
Number who died from confirmed or probable TB
Time Frame
two years
Title
TPT uptake: number screen-negatives prescribed TPT
Description
Number of screen-negatives prescribed TPT
Time Frame
two years
Title
TPT uptake: number screen-positives prescribed TPT
Description
Number screen-positives prescribed TPT
Time Frame
two years
Title
TPT uptake: number initiated on TPT
Description
Number screen-negatives prescribed TPT + number screen-positives prescribed TPT
Time Frame
two years
Title
TPT uptake: time to TPT initiation
Description
Days from baseline TB screening to initiation of TPT
Time Frame
two years
Title
TPT uptake: number completing TPT
Description
Number initiated on TPT who completed ≥90% of treatment over prescribed TPT period
Time Frame
two years
Title
Prevalent TB diagnosis: number microbiologically-confirmed prevalent TB cases detected by screening test
Description
Number screen-positives diagnosed with prevalent TB
Time Frame
two years
Title
Prevalent TB diagnosis: number microbiologically-confirmed prevalent TB cases missed by screening test
Description
Number screen-negatives diagnosed with prevalent TB
Time Frame
two years
Title
Prevalent TB diagnosis: number diagnosed with microbiologically-confirmed prevalent TB
Description
Number screen-positives diagnosed with prevalent TB + number screen-negatives diagnosed with prevalent TB
Time Frame
two years
Title
Prevalent TB treatment: Number treated for prevalent TB
Description
Number initiated on TB treatment 3 months or less after study entry
Time Frame
two years
Title
Prevalent TB treatment: number with microbiologically-confirmed prevalent TB completing treatment
Description
Number diagnosed and treated who completed treatment
Time Frame
two years
Title
Prevalent TB treatment: time to treatment of microbiologically-confirmed prevalent TB
Description
Days from prevalent TB diagnosis to initiation of TB treatment
Time Frame
two years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Confirmed HIV+ test result CD4 T lymphocyte count of ≤ 350 cells/μL Capacity to provide written (or witnessed verbal, if illiterate) informed consent Exclusion Criteria: Completed treatment for active pulmonary or extra-pulmonary TB within the past 2 years Completed a full course of TPT within the past year Actively taking any internationally-approved medication for TB treatment for any reason, within 2 weeks of study entry Prior history of combined ART for HIV treatment for any duration (does not include single-dose ART for prevention of vertical transmission of HIV) Currently resides 25 km outside their enrollment site, plans to move 25 km outside their enrollment site in the next 2 years, or plans to transfer their HIV care from their current enrollment site
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christina Yoon, MD
Phone
+1 628-206-3514
Email
Christina.Yoon@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christina Yoon, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kampala Capital City Authority Clinic
City
Kampala
Country
Uganda
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fred Semitala, MMed

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
Citation
WHO. Global Tuberculosis Report 2017. Geneva, Switzerland. World Health Organization 2017.
Results Reference
background
PubMed Identifier
23954450
Citation
Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013 Oct;13(10):852-8. doi: 10.1016/S1473-3099(13)70187-7. Epub 2013 Aug 16.
Results Reference
background
PubMed Identifier
26193126
Citation
TEMPRANO ANRS 12136 Study Group; Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpe JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouame A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibe B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouame E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundze S, Hawerlander D, Ani A, Dembele F, Kone F, Guehi C, Kanga C, Koule S, Seri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoue G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semde C, Kouame A, Massumbuko JM, Chene G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholie SP, Anglaret X. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808-22. doi: 10.1056/NEJMoa1507198. Epub 2015 Jul 20.
Results Reference
background
PubMed Identifier
24835842
Citation
Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E, Maartens G. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014 Aug 23;384(9944):682-90. doi: 10.1016/S0140-6736(14)60162-8. Epub 2014 May 13.
Results Reference
background
PubMed Identifier
15941800
Citation
Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, De Cock KM, Hayes RJ, Churchyard GJ. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA. 2005 Jun 8;293(22):2719-25. doi: 10.1001/jama.293.22.2719.
Results Reference
background
PubMed Identifier
24450889
Citation
Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, Hayes RJ, Chaisson RE, Grant AD; Thibela TB Study Team. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014 Jan 23;370(4):301-10. doi: 10.1056/NEJMoa1214289.
Results Reference
background
Citation
WHO. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland. World Health Organization 2011.
Results Reference
background
PubMed Identifier
30277688
Citation
Latent tuberculosis infection: updated and consolidated guidelines for programmatic management [Internet]. Geneva: World Health Organization; 2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK531235/
Results Reference
background
PubMed Identifier
21267059
Citation
Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard GJ, Kimerling M, Shah S, Lawn SD, Wood R, Maartens G, Granich R, Date AA, Varma JK. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011 Jan 18;8(1):e1000391. doi: 10.1371/journal.pmed.1000391.
Results Reference
background
Citation
WHO. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva, Switzerland. World Health Organization 2014.
Results Reference
background
PubMed Identifier
21818180
Citation
Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011 Jul;8(7):e1001067. doi: 10.1371/journal.pmed.1001067. Epub 2011 Jul 26.
Results Reference
background
PubMed Identifier
22627184
Citation
Kufa T, Mngomezulu V, Charalambous S, Hanifa Y, Fielding K, Grant AD, Wada N, Chaisson RE, Churchyard GJ, Gounder CR. Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):e22-8. doi: 10.1097/QAI.0b013e318251ae0b.
Results Reference
background
PubMed Identifier
23485388
Citation
Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, Gupta A, Veloso VG, Asmelash A, Omoz-Oarhe AE, Gengiah S, Lalloo U, Allen R, Shiboski C, Andersen J, Qasba SS, Katzenstein DK; AIDS Clinical Trials Group 5253 Study Team. Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253. Int J Tuberc Lung Dis. 2013 Apr;17(4):532-9. doi: 10.5588/ijtld.12.0737.
Results Reference
background
PubMed Identifier
27393536
Citation
Henostroza G, Harris JB, Chitambi R, Siyambango M, Turnbull ER, Maggard KR, Kruuner A, Kapata N, Reid SE. High prevalence of tuberculosis in newly enrolled HIV patients in Zambia: need for enhanced screening approach. Int J Tuberc Lung Dis. 2016 Aug;20(8):1033-9. doi: 10.5588/ijtld.15.0651.
Results Reference
background
PubMed Identifier
13354933
Citation
DERBES VJ, JACOBS S, LINN RH, TURNER M, WALSH JJ. C-reactive protein in pulmonary tuberculosis. Am Rev Tuberc. 1956 Sep;74(3):464-7. doi: 10.1164/artpd.1956.74.3.464. No abstract available.
Results Reference
background
PubMed Identifier
2555173
Citation
Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 1989 Dec 1;8(12):3773-9. doi: 10.1002/j.1460-2075.1989.tb08554.x.
Results Reference
background
PubMed Identifier
1879927
Citation
Ogawa T, Uchida H, Kusumoto Y, Mori Y, Yamamura Y, Hamada S. Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis. Infect Immun. 1991 Sep;59(9):3021-5. doi: 10.1128/iai.59.9.3021-3025.1991.
Results Reference
background
PubMed Identifier
7932624
Citation
Saunders R, Robson S, Soule S, Kirsch RE. Secretion of interleukin-6 by peripheral blood mononuclear cells from patients with pulmonary tuberculosis and their contacts. J Clin Lab Immunol. 1993;40(1):19-28.
Results Reference
background
PubMed Identifier
8125515
Citation
Flesch IE, Kaufmann SH. Role of cytokines in tuberculosis. Immunobiology. 1993 Nov;189(3-4):316-39. doi: 10.1016/S0171-2985(11)80364-5.
Results Reference
background
PubMed Identifier
9359411
Citation
Weinhold B, Ruther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J. 1997 Oct 15;327 ( Pt 2)(Pt 2):425-9. doi: 10.1042/bj3270425.
Results Reference
background
PubMed Identifier
9971870
Citation
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 Feb 11;340(6):448-54. doi: 10.1056/NEJM199902113400607. No abstract available. Erratum In: N Engl J Med 1999 Apr 29;340(17):1376.
Results Reference
background
PubMed Identifier
11280064
Citation
Lawn SD, Wiktor S, Coulibaly D, Ackah AN, Lal RB. Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg. 2001 Jan-Feb;95(1):41-2. doi: 10.1016/s0035-9203(01)90328-1. No abstract available.
Results Reference
background
PubMed Identifier
12571508
Citation
Kihara M, Kamakura M, Feldman MD. Introduction: HIV/AIDS surveillance in a new era. J Acquir Immune Defic Syndr. 2003 Feb;32 Suppl 1:S1-2. doi: 10.1097/00126334-200302011-00001. No abstract available.
Results Reference
background
PubMed Identifier
17885297
Citation
Drain PK, Kupka R, Msamanga GI, Urassa W, Mugusi F, Fawzi WW. C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS. 2007 Oct 1;21(15):2067-75. doi: 10.1097/QAD.0b013e32826fb6c7.
Results Reference
background
PubMed Identifier
18942885
Citation
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008 Oct 21;5(10):e203. doi: 10.1371/journal.pmed.0050203.
Results Reference
background
PubMed Identifier
20871387
Citation
Tien PC, Schneider MF, Cox C, Cohen M, Karim R, Lazar J, Young M, Glesby MJ. HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study. AIDS. 2010 Nov 27;24(18):2809-17. doi: 10.1097/QAD.0b013e32833fcb3b.
Results Reference
background
PubMed Identifier
20446848
Citation
Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010 Jun 15;201(12):1788-95. doi: 10.1086/652749.
Results Reference
background
PubMed Identifier
20863238
Citation
Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ; AIDS Clinical Trials Group A5095 Study Team. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses. 2011 May;27(5):461-8. doi: 10.1089/aid.2010.0154. Epub 2010 Nov 23.
Results Reference
background
PubMed Identifier
10777083
Citation
Lawn SD, Obeng J, Acheampong JW, Griffin GE. Resolution of the acute-phase response in West African patients receiving treatment for pulmonary tuberculosis. Int J Tuberc Lung Dis. 2000 Apr;4(4):340-4.
Results Reference
background
PubMed Identifier
12797485
Citation
Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, Arndt G, Lode H. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J. 2003 Jun;21(6):939-43. doi: 10.1183/09031936.03.00055103.
Results Reference
background
PubMed Identifier
15802344
Citation
Schleicher GK, Herbert V, Brink A, Martin S, Maraj R, Galpin JS, Feldman C. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J. 2005 Apr;25(4):688-92. doi: 10.1183/09031936.05.00067604.
Results Reference
background
PubMed Identifier
17263297
Citation
Choi CM, Kang CI, Jeung WK, Kim DH, Lee CH, Yim JJ. Role of the C-reactive protein for the diagnosis of TB among military personnel in South Korea. Int J Tuberc Lung Dis. 2007 Feb;11(2):233-6.
Results Reference
background
PubMed Identifier
18173876
Citation
Breen RA, Leonard O, Perrin FM, Smith CJ, Bhagani S, Cropley I, Lipman MC. How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis? Int J Tuberc Lung Dis. 2008 Jan;12(1):44-9.
Results Reference
background
PubMed Identifier
19949732
Citation
Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med. 2009 Dec;24(4):337-42. doi: 10.3904/kjim.2009.24.4.337. Epub 2009 Nov 27.
Results Reference
background
PubMed Identifier
20378904
Citation
Sage EK, Noursadeghi M, Evans HE, Parker SJ, Copas AJ, Edwards SG, Miller RF. Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia. Int J STD AIDS. 2010 Apr;21(4):288-92. doi: 10.1258/ijsa.2010.009551.
Results Reference
background
PubMed Identifier
21249220
Citation
Wilson D, Badri M, Maartens G. Performance of serum C-reactive protein as a screening test for smear-negative tuberculosis in an ambulatory high HIV prevalence population. PLoS One. 2011 Jan 10;6(1):e15248. doi: 10.1371/journal.pone.0015248.
Results Reference
background
PubMed Identifier
23575330
Citation
Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. Int J Tuberc Lung Dis. 2013 May;17(5):636-43. doi: 10.5588/ijtld.12.0811.
Results Reference
background
PubMed Identifier
24346636
Citation
Yoon C, Davis JL, Huang L, Muzoora C, Byakwaga H, Scibetta C, Bangsberg DR, Nahid P, Semitala FC, Hunt PW, Martin JN, Cattamanchi A. Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV. J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):551-6. doi: 10.1097/QAI.0000000000000085.
Results Reference
background
PubMed Identifier
28826451
Citation
Yoon C, Chaisson LH, Patel SM, Allen IE, Drain PK, Wilson D, Cattamanchi A. Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. 2017 Sep 1;21(9):1013-1019. doi: 10.5588/ijtld.17.0078.
Results Reference
background
PubMed Identifier
29847333
Citation
Shapiro AE, Hong T, Govere S, Thulare H, Moosa MY, Dorasamy A, Wallis CL, Celum CL, Grosset J, Drain PK. C-reactive protein as a screening test for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy in South Africa. AIDS. 2018 Aug 24;32(13):1811-1820. doi: 10.1097/QAD.0000000000001902.
Results Reference
background
PubMed Identifier
28847636
Citation
Yoon C, Semitala FC, Atuhumuza E, Katende J, Mwebe S, Asege L, Armstrong DT, Andama AO, Dowdy DW, Davis JL, Huang L, Kamya M, Cattamanchi A. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2017 Dec;17(12):1285-1292. doi: 10.1016/S1473-3099(17)30488-7. Epub 2017 Aug 25.
Results Reference
background
PubMed Identifier
30192649
Citation
Yoon C, Semitala FC, Asege L, Katende J, Mwebe S, Andama AO, Atuhumuza E, Nakaye M, Armstrong DT, Dowdy DW, McCulloch CE, Kamya M, Cattamanchi A. Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV. Am J Respir Crit Care Med. 2019 Mar 1;199(5):643-650. doi: 10.1164/rccm.201803-0490OC.
Results Reference
background
PubMed Identifier
30462176
Citation
Rajan JV, Semitala FC, Mehta T, Seielstad M, Montalvo L, Andama A, Asege L, Nakaye M, Katende J, Mwebe S, Kamya MR, Yoon C, Cattamanchi A. A Novel, 5-Transcript, Whole-blood Gene-expression Signature for Tuberculosis Screening Among People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019 Jun 18;69(1):77-83. doi: 10.1093/cid/ciy835.
Results Reference
background
PubMed Identifier
30649057
Citation
Chaisson LH, Semitala FC, Asege L, Mwebe S, Katende J, Nakaye M, Andama AO, Marquez C, Atuhumuza E, Kamya M, Cattamanchi A, Yoon C. Point-of-care C-reactive protein and risk of early mortality among adults initiating antiretroviral therapy. AIDS. 2019 Apr 1;33(5):895-902. doi: 10.1097/QAD.0000000000002130.
Results Reference
background
PubMed Identifier
31658185
Citation
Semitala FC, Cattamanchi A, Andama A, Atuhumuza E, Katende J, Mwebe S, Asege L, Nakaye M, Kamya MR, Yoon C. Brief Report: Yield and Efficiency of Intensified Tuberculosis Case-Finding Algorithms in 2 High-Risk HIV Subgroups in Uganda. J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):416-420. doi: 10.1097/QAI.0000000000002162.
Results Reference
background
Citation
Uganda Ministry of Health. Report on the Population-based survey of prevalence of tuberculosis disease in Uganda 2014-2015. Kampala: MOH, 2017.
Results Reference
background
Citation
PEPFAR Uganda Program data. (https://www.pepfar.gov/documents/organization/285851.)
Results Reference
background
Citation
Yung-Pin C. Biased coin design with imbalance tolerance. Stochastic Models. 1999 Jan 1;15(5):953-75. doi: 10.1080/15326349908807570
Results Reference
background
PubMed Identifier
19104782
Citation
Pfafflin A, Schleicher E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem. 2009 Mar;393(5):1473-80. doi: 10.1007/s00216-008-2561-3. Epub 2008 Dec 23.
Results Reference
background
PubMed Identifier
1245780
Citation
Claus DR, Osmand AP, Gewurz H. Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med. 1976 Jan;87(1):120-8.
Results Reference
background
PubMed Identifier
31577875
Citation
Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A; IMPAACT P1078 TB APPRISE Study Team. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. doi: 10.1056/NEJMoa1813060.
Results Reference
background
Citation
Uganda Ministry of Health. Isoniazid preventive therapy in Uganda: a health worker's guide. Kampala: MOH, 2014.
Results Reference
background
PubMed Identifier
35550621
Citation
Semitala FC, Chaisson LH, Dowdy DW, Armstrong DT, Opira B, Aman K, Kamya M, Phillips PPJ, Yoon C. Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial. Trials. 2022 May 12;23(1):399. doi: 10.1186/s13063-022-06371-0.
Results Reference
derived

Learn more about this trial

TB Screening Improves Preventive Therapy Uptake

We'll reach out to this number within 24 hrs